T1D Exchange has announced the launch of a new T1DExchange.org website featuring cutting-edge connectivity to better serve the type 1 diabetes community and leverage technology, including a biobank, to accelerate therapies and improve care for people affected by type 1 diabetes, approximately 1.25 million people in the USA alone.
T1D Exchange is a non-profit research organization, founded in 2011, headquartered in Boston, Massachusetts, USA, dedicated to accelerating therapies and improving care for people affected by type 1 diabetes.
The T1D Exchange model uses cutting-edge tools, research methods, and a robust IT platform to gather evidence from the real-world and clinical experiences of people living with type 1 diabetes.
T1D Exchange actively supports discovery and innovation through its biobank and patient data. At the same time, the organization understands that evidence gathered in the “real world” can help bridge the gap between discovery in research settings and impact in people’s lives.
The goal is to connect biological samples, medical data, and patient insights to all stages of research and development, expediting the development of therapies and better care for everyone affected by type 1 diabetes.
T1DExchange.org is a user-friendly, easy-to-navigate, one-stop resource for the type 1 diabetes community featuring:
- Vetted and validated content
- Regular questions and answers, polls and results on issues facing people with type 1 diabetes
- News about the latest advances in care
- Regulatory and public policy updates
- Easy connectivity for users to share content on social media
- Direct connectivity to T1D Exchange Glu, the online community of more than 23,000 active users
- A gateway to the T1D Exchange Biobank, a collection of biological samples used by researchers and linked to the data of more than 2,200 people with type 1 diabetes
Additionally, T1DExchange.org will soon include new features that are especially important to advancing and accelerating care for type 1 diabetes.
- A more robust and expanded T1D Registry that gives people with type 1 diabetes opportunities to participate in the latest T1D Exchange-research aimed at accelerating care solutions, and influencing public policy and insurance regulations. Since 2010, more than 35,000 people with type 1 diabetes have registered to participate in research through T1D Exchange resulting in more than 75 published studies.
- A Quality Improvement portal where participating clinics can upload full data on patient outcomes and the state of care. This data will be used to identify best practices, gaps in access to care, and reimbursement and public policy issues.
- Future connectivity to the Tidepool Big Data Donation Project that shares de-identified diabetes device data with researchers, device makers and other innovators working to advance diabetes care.
“T1D Exchange was founded on the belief that improving outcomes requires better, faster, patient-driven research that produces the real-world evidence needed to advance promising therapies, improve access to care, and influence reimbursement for that care,” … “What we are announcing today is more than just a website. It is the most advanced platform in the type 1 diabetes community to put patients at the forefront and to give them the resources they need to live better.” – Dara P. Schuster, MD, CEO of T1D Exchange
“Until today, I have had to go to multiple sources to find information and resources to connect with others in the type 1 diabetes community, or to learn about the latest research and be a part of it,” … “The new T1D Exchange platform gives me all of that without having to search and click around the web.” – Jack Collins, a T1D Exchange board member and a type 1 diabetes patient
“It is so difficult sometimes to find the myriad of data we as researchers need to advance a study or start a new one,” … “The platform’s single source access to this data will accelerate our ability to uncover more about type 1 diabetes and develop new therapies to improve care.” – Alborz Mahdavi, PhD, Founder and CEO of Protomer Technologies and winner of the top prize in the 2018 T1D Exchange Diabetes Innovation Challenge.